ClinicalTrials.gg
TerminatedNCT04149574CheckMate 7G8Updated Sep 16, 2025Results posted

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

A Phase 3 interventional study of nivolumab and Placebo in Urinary Bladder Neoplasms, sponsored by Bristol-Myers Squibb. Terminated at 63 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was terminated
Insufficient enrollment, inability to meet protocol objectives, and slow accrual.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing nivolumab in Urinary Bladder Neoplasms — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Urinary Bladder Neoplasms.

Enrollment
24th of 25
13 · median 76
Started
2020
with 2 others
Phase 3
4 of 25
none open now
Registered
17th of 25
by date
Lead sponsor
5 of 25
Bristol-Myers Squibb

Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, this one is the 24th largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 17th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

3 of the 25 studies testing nivolumab in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing nivolumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.

03

Conditions studied

  • Urinary Bladder Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persistent or recurrent disease ≤ 24 months of last BCG dose, but not classified as BCG unresponsive
  • confirmed persistent or recurrent high-risk non-muscle-invasive urothelial carcinoma (UC)
  • Treated with at least 1 adequate course of induction BCG therapy (at least 5 out of 6 doses)
  • (ECOG) performance status (PS) 0-2

Exclusion criteria

Exclusion Criteria:

  • Previous or concurrent muscle invasive, locally advanced, or disseminated/ UC
  • UC in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment
  • UC and/or CIS in the prostatic urethra within 12 months of enrollment

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Arm A: nivolumab + Bacillus Calmette-Guérin (BCG)

    Drug: nivolumab · Biological: Bacillus Calmette-Guérin (BCG)

  • Placebo comparator
    Arm B: placebo +BCG

    Other: Placebo · Biological: Bacillus Calmette-Guérin (BCG)

Interventions

06

What researchers measure

Primary outcomes

  1. Part 2: Event Free Survival

    The time between the date of randomization and the date of first documented event or death due to any cause, whichever occurs first. Events include recurrence of disease (TaHG, T1, or CIS) and progression of disease. Data Not Collected (DNC)

    Time frame: Approximately 44 Months and 1 Week

Secondary outcomes

  1. Part 2: Worsening-Free Survival

    The time from randomization to progression to muscle-invasive disease (ie, T2), cystectomy, systemic chemotherapy, radiotherapy, or death from any cause. Data Not Collected (DNC)

    Time frame: Approximately 44 months and 1 week

  2. Part 2: Overall Survival

    The time between the date of randomization and the date of death due to any cause. For participants still alive, OS is censored at the last date the participant is known to be alive. Data Not Collected (DNC)

    Time frame: Approximately 44 months and 1 week

  3. Part 2: Complete Response Rate at 13 Weeks

    CRR is defined as the proportion of participants with CIS (+/- TaHG/T1) per PRC at randomization who are disease free at the first disease assessment (Week 13) Data Not Collected (DNC)

    Time frame: 13 Weeks

  4. Part 2: Duration of Response

    the time between the date of the first CR to the date of first documented recurrence, progression, or death due to any cause. Data Not Collected (DNC)

    Time frame: Approximately 44 months and 1 week

  5. All-causality Adverse Events Leading to Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.

    Time frame: 24.6 months

  6. All-causality Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.

    Time frame: 24.6 months

  7. Drug-related Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.

    Time frame: 24.6 months

07

Results

Posted Sep 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm AArm B
Started84
Completed84
Not completed00

Outcome measures

PrimaryPart 2: Event Free Survival

The time between the date of randomization and the date of first documented event or death due to any cause, whichever occurs first. Events include recurrence of disease (TaHG, T1, or CIS) and progression of disease. Data Not Collected (DNC)

Time frame:
Approximately 44 Months and 1 Week

No measurements were reported for this outcome.

SecondaryPart 2: Worsening-Free Survival

The time from randomization to progression to muscle-invasive disease (ie, T2), cystectomy, systemic chemotherapy, radiotherapy, or death from any cause. Data Not Collected (DNC)

Time frame:
Approximately 44 months and 1 week

No measurements were reported for this outcome.

SecondaryPart 2: Overall Survival

The time between the date of randomization and the date of death due to any cause. For participants still alive, OS is censored at the last date the participant is known to be alive. Data Not Collected (DNC)

Time frame:
Approximately 44 months and 1 week

No measurements were reported for this outcome.

SecondaryPart 2: Complete Response Rate at 13 Weeks

CRR is defined as the proportion of participants with CIS (+/- TaHG/T1) per PRC at randomization who are disease free at the first disease assessment (Week 13) Data Not Collected (DNC)

Time frame:
13 Weeks

No measurements were reported for this outcome.

SecondaryPart 2: Duration of Response

the time between the date of the first CR to the date of first documented recurrence, progression, or death due to any cause. Data Not Collected (DNC)

Time frame:
Approximately 44 months and 1 week

No measurements were reported for this outcome.

SecondaryAll-causality Adverse Events Leading to Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.

Time frame:
24.6 months
Reported as:
Count of participants · Participants
All-causality Adverse Events Leading to Discontinuation
ParticipantsArm AArm B
Any Grade13
Grade 3-400
Grade 500
SecondaryAll-causality Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.

Time frame:
24.6 months
Reported as:
Count of participants · Participants
All-causality Adverse Events
ParticipantsArm AArm B
Grade 112
Grade 241
Grade 311
SecondaryDrug-related Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.

Time frame:
24.6 months
Reported as:
Count of participants · Participants
Drug-related Adverse Events
ParticipantsArm AArm B
Grade 111
Grade 241
Grade 311

Adverse events

Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose + 100 days): Approximately 44 months and 1 week All-Cause mortality (From randomization to end of study): Approximately 44 months and 1 week. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A0/8 (0%)2/8 (25%)5/8 (62.5%)
Arm B0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventArm AArm B
CystitisInfections and infestations1/80/4
Urinary tract infectionInfections and infestations1/80/4
Most frequent other events
Showing 10 of 51
Most frequent other events
EventArm AArm B
Urinary tract infectionInfections and infestations3/83/4
DysuriaRenal and urinary disorders3/81/4
AnaemiaBlood and lymphatic system disorders2/80/4
DiarrhoeaGastrointestinal disorders2/80/4
Umbilical herniaGastrointestinal disorders0/81/4
AstheniaGeneral disorders0/81/4
PainGeneral disorders0/81/4
CystitisInfections and infestations1/81/4
GastroenteritisInfections and infestations0/81/4
Cortisol decreasedInvestigations0/81/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm AArm BTotal
Mean61.1 ± 9.873.0 ± 15.365.1 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female112
Male7310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm AArm BTotal
Hispanic or Latino123
Not Hispanic or Latino516
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm AArm BTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White7411
More than one race000
Unknown or Not Reported000
08

Study locations

63 sites
  • The University Of Chicago
    Chicago, Illinois 60637, United States
  • Local Institution - 0084
    The Bronx, New York 10461, United States
  • Local Institution - 0009
    Caba, Buenos Aires 1426, Argentina
  • Local Institution - 0088
    Capital Federal, Buenos Aires 1419, Argentina
  • Local Institution - 0016
    Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
  • Local Institution - 0081
    Mar del Plata, Buenos Aires 7600, Argentina
  • Local Institution - 0008
    Viedma, Río Negro Province 8500, Argentina
  • Local Institution - 0080
    Buenos Aires, 1120, Argentina
  • Local Institution - 0107
    Córdoba, 5000, Argentina
  • Local Institution - 0002
    Sydney, New South Wales 2050, Australia
  • Local Institution - 0001
    Woolloongabba, Queensland 4012, Australia
  • Local Institution - 0114
    Bowral, 2576, Australia
  • Local Institution - 0097
    Linz, 4010, Austria
  • Local Institution - 0104
    Salzburger, 5020, Austria
  • Local Institution - 0099
    Vienna, 1090, Austria
  • Local Institution - 0098
    Wels, 4600, Austria
  • Local Institution - 0050
    Uberlândia, Minas Gerais 38408-150, Brazil
  • Local Institution - 0048
    Porto Alegre, Rio Grande do Sul 90035-001, Brazil
  • Local Institution - 0047
    Itajaí, Santa Catarina 88301-220, Brazil
  • Local Institution - 0049
    Rio de Janeiro, 22793-080, Brazil
  • Local Institution - 0017
    Toronto, Ontario M5G 1Z5, Canada
  • Local Institution - 0038
    Montreal, Quebec H2X 0C2, Canada
  • Local Institution - 0037
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0012
    Rimouski, Quebec G5L 5T1, Canada
  • Local Institution - 0011
    La Serena, Coquimbo Region 1720430, Chile
  • Local Institution - 0010
    Recoleta, Santiago Metropolitan 0, Chile
  • Local Institution - 0072
    Viña del Mar, Valparaiso 2520598, Chile
  • Local Institution - 0042
    Angers, 49933, France
  • Local Institution - 0106
    Dijon, 21079, France
  • Local Institution - 0045
    Lille, 59000, France
  • Local Institution - 0108
    Marseille, 13385, France
  • Local Institution - 0111
    Paris, 75018, France
  • Local Institution - 0103
    Paris, 75679, France
  • Local Institution - 0041
    Strasbourg, FR-67091, France
  • Local Institution - 0040
    Villejuif, 94800, France
  • Local Institution - 0105
    Cologne, 50968, Germany
  • Local Institution - 0094
    Herne, 44625, Germany
  • Local Institution - 0093
    Jena, 07747, Germany
  • Local Institution - 0095
    Trier, 54292, Germany
  • Local Institution - 0031
    Haidari, 12462, Greece
  • Local Institution - 0032
    Thessaloniki, 57001, Greece
  • Local Institution - 0075
    Tel Aviv, Tel Aviv 6423906, Israel
  • Local Institution - 0073
    Jerusalem, 9103102, Israel
  • Local Institution - 0074
    Ramat Gan, 52621, Israel
  • Local Institution - 0067
    Torino, TO 10126, Italy
  • Local Institution - 0062
    Milan, 20133, Italy
  • Local Institution - 0063
    Modena, 41124, Italy
  • Local Institution - 0064
    Naples, 80131, Italy
  • Local Institution - 0065
    Reggio Emilia, 42100, Italy
  • Local Institution - 0066
    Roma, 00168, Italy
  • Local Institution - 0054
    Arnhem, 6815 AD, Netherlands
  • Local Institution
    Rotterdam, 3015 GD, Netherlands
  • Local Institution - 0051
    Moscow, 121309, Russia
  • Local Institution - 0052
    Saint Petersburg, 199034, Russia
  • Local Institution - 0096
    Pamplona, Navarre 31008, Spain
  • Local Institution - 0061
    Badajoz, 06006, Spain
  • Local Institution - 0060
    Badalona-barcelona, 08916, Spain
  • Local Institution - 0055
    Madrid, 28041, Spain
  • Local Institution - 0059
    Sabadell, 08208, Spain
  • Local Institution - 0057
    Santander, 39008, Spain
  • Local Institution - 0058
    Valencia, 46010, Spain
  • Local Institution - 0087
    Norrköping, 601 82, Sweden
  • Local Institution - 0083
    Umeå, 901 85, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Oct 2023, 45 months.

Results were first posted in Sep 2025, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2019
First posted
Nov 4, 2019
StartActual
Jan 15, 2020
Primary completionActual
Oct 31, 2023
CompletionActual
Oct 31, 2023
Results first posted
Sep 16, 2025
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04149574
Responsible party
Sponsor
First posted
Nov 4, 2019
Start date
Jan 15, 2020
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Results posted
Sep 16, 2025
Last update
Sep 16, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion